CN106619680A - Western medicine for treating chronic respiratory failure - Google Patents
Western medicine for treating chronic respiratory failure Download PDFInfo
- Publication number
- CN106619680A CN106619680A CN201611189083.9A CN201611189083A CN106619680A CN 106619680 A CN106619680 A CN 106619680A CN 201611189083 A CN201611189083 A CN 201611189083A CN 106619680 A CN106619680 A CN 106619680A
- Authority
- CN
- China
- Prior art keywords
- parts
- western medicine
- chronic respiratory
- respiratory failure
- glycosides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
- A61K31/37—Coumarins, e.g. psoralen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses a western medicine for treating chronic respiratory failure. The western medicine for treating the chronic respiratory failure is prepared from main raw materials in parts by weight as follows; 9-13 parts of imperialine-e-D-glocoside, 25-30 parts of halofuginone, 7-10 parts of osmundacetone, 2-3 parts of 3-acetyl-11-keto-boswellic acid, 15-20 parts of tiliroside, 8-16 parts of jatrorrhizine hydrochloride, 5-14 parts of corynoline, 2-8 parts of etoposide, 9-12 parts of lupeol and 5-7 parts of isofraxidin. Components of raw materials of the medicine are strictly selected according to the knowledge mechanism of the chronic respiratory failure, so that the purpose of comprehensive recovery is achieved. The western medicine has the characteristics of taking effect quickly, acting stably, being convenient to carry and take and having no toxic or side effects.
Description
Technical field
The present invention relates to a kind of field of medicine preparation, specifically a kind of Western medicine for treating chronic respiratory failure.
Background technology
It is chronic exhale to decline be secondary to chronic respiratory disease, such as chronic obstructive pulmonary disease, far advanced tuberculosis more；Its breathing
Functional lesion gradually increases, though having anoxic and carbon dioxide retention, by the compensatory adaptation of body, is still engaged in personal lifestyle, claims
For chronic respiratory failure；Once generation respiratory tract infection, or because other reasonses increase physiology of respiration burden, then compensatory mistake
Adjust, the clinical manifestation of severe depletion of oxygen, carbon dioxide retention and respiratory acidosis occur, referred to as decompensation chronic respiratory declines
Exhaust.Respiratory failure is anoxic or with carbon dioxide pool caused by the ventilation and (or) dysfunction of ventilation caused by various diseases
Stay.Under sea level breathing atmospheric conditions, arterial partial pressure of oxygen (PaO2) is less than 8kPa and arterial partial pressure of carbon dioxide
(PaCO2) it is higher than 6.66kPa, and produces the clinical syndrome of serial pathophysiological change and metabolic disorder.Lung governing qi, can exhale
Inhale, clear gas, breathes out foul smell in suction air, communicates with air, be the hinge of mechanism of qi discrepancy lifting.Lung being a delicate viscus, outer conjunction fur.
Exopathogen attack human body attacking the lung first, impairment of dispersing and descending function of the lung and send out cough and asthma.If obstinate disease can cause deficiency and damage of lung-QI, and involve spleen kidney.The deficiency syndrome of the lung
The operation for administering painstaking effort can not be adjusted, then motive heart-yang also virtual loss, eventually to lung, spleen, kidney, all void of the heart and become the morbidity base of this disease
Plinth.The factors such as climate change, diet, feelings will and fatigue, then can induce for this disease.Lack effective medicine at present.
The content of the invention
It is an object of the invention to provide a kind of Western medicine for treating chronic respiratory failure, to solve above-mentioned background technology in carry
The problem for going out.
For achieving the above object, the present invention provides following technical scheme：
A kind of Western medicine for treating chronic respiratory failure, be according to the primary raw material of weight portion：BULBUS FRITILLARIAE CIRRHOSAE element glycosides 9-13 parts, often
Mountain ketone 25-30 parts, osmund ketone 7-10 parts, 3- acetyl group -11- ketone group masticinic acid 2-3 parts, silver forging glycosides 15-20 parts, jateorrhizine hydrochloric acid
Salt 8-16 parts, corynoline 5-14 parts, support pool 2-8 parts, lupeol 9-12 parts, isofraxidin 5-7 parts.
As further scheme of the invention：The Western medicine of the treatment chronic respiratory failure, according to the main original of weight portion
Expect be：BULBUS FRITILLARIAE CIRRHOSAE element glycosides 10-11 parts, halofuginone hydrobromide 26-28 parts, osmund ketone 8-9 parts, 3- acetyl group -11- ketone group masticinic acid 2-3 parts,
Silver forging glycosides 16-19 parts, jateorrhizine hydrochloride 12-15 parts, corynoline 7-12 parts, rely on pool 3-7 parts, lupeol 10-11 parts, different
Piperazine skin pyridine 5-7 parts.
As further scheme of the invention：The Western medicine of the treatment chronic respiratory failure, according to the main original of weight portion
Expect be：BULBUS FRITILLARIAE CIRRHOSAE 11 parts of glycosides of element, 27 parts of halofuginone hydrobromide, 9 parts of osmund ketone, 3 parts of 3- acetyl group -11- ketone groups masticinic acid, silver forging glycosides 18
Part, 14 parts of jateorrhizine hydrochloride, 9 parts of corynoline, 5 parts of support pool, 11 parts of lupeol, 6 parts of isofraxidin.
A kind of preparation method of the Western medicine for treating chronic respiratory failure, concretely comprises the following steps：
First, in pharmaceutical grade clean area, BULBUS FRITILLARIAE CIRRHOSAE element glycosides, halofuginone hydrobromide, osmund ketone, 3- acetyl are weighed by above-mentioned metering ratio
Base -11- ketone group masticinic acids, silver forging glycosides, jateorrhizine hydrochloride, corynoline, support pool, lupeol, isofraxidin, sieve, machine
Tool adds ultra-pure water after mixing, in placing pharmacy mixer, mix 4-8min, controls RSD≤5%, compressing tablet and low temperature after mixing
It is dried, at 4-8 DEG C, packaging obtains final product the Western medicine for the treatment of chronic respiratory failure to temperature control.
As further scheme of the invention：Mix 6min in concrete steps.
Compared with prior art, the invention has the beneficial effects as follows：
Medicine of the present invention is strictly selected material composition according to the understanding mechanism of chronic respiratory failure, complete so as to reach
The purpose of face rehabilitation, with rapid-action, effect it is stable, carry taking convenience, long-term taking and have no toxic side effect the characteristics of.
Specific embodiment
Below in conjunction with the embodiment of the present invention, the technical scheme in the embodiment of the present invention is clearly and completely described,
Obviously, described embodiment is only a part of embodiment of the invention, rather than the embodiment of whole.Based in the present invention
Embodiment, the every other embodiment that those of ordinary skill in the art are obtained under the premise of creative work is not made, all
Belong to the scope of protection of the invention.
Embodiment 1
A kind of Western medicine for treating chronic respiratory failure, be according to the primary raw material of weight portion：BULBUS FRITILLARIAE CIRRHOSAE 9 parts of glycosides of element, Changshan
25 parts of ketone, 7 parts of osmund ketone, 2 parts of 3- acetyl group -11- ketone groups masticinic acid, silver 15 parts of glycosides of forging, 8 parts of jateorrhizine hydrochloride, corynoline 5
Part, 2 parts of support pool, 9 parts of lupeol, 5 parts of isofraxidin.
A kind of preparation method of the Western medicine for treating chronic respiratory failure, concretely comprises the following steps：
First, in pharmaceutical grade clean area, BULBUS FRITILLARIAE CIRRHOSAE element glycosides, halofuginone hydrobromide, osmund ketone, 3- acetyl are weighed by above-mentioned metering ratio
Base -11- ketone group masticinic acids, silver forging glycosides, jateorrhizine hydrochloride, corynoline, support pool, lupeol, isofraxidin, sieve, machine
Tool adds ultra-pure water after mixing, in placing pharmacy mixer, mix 4min, controls RSD≤5%, and compressing tablet simultaneously do by low temperature after mixing
Dry, at 4 DEG C, packaging obtains final product the Western medicine for the treatment of chronic respiratory failure to temperature control.
Embodiment 2
A kind of Western medicine for treating chronic respiratory failure, be according to the primary raw material of weight portion：BULBUS FRITILLARIAE CIRRHOSAE 10 parts of glycosides of element, Changshan
26 parts of ketone, 8 parts of osmund ketone, 2 parts of 3- acetyl group -11- ketone groups masticinic acid, silver 16 parts of glycosides of forging, 12 parts of jateorrhizine hydrochloride, corynoline
7 parts, rely on pool 3 parts, 10 parts of lupeol, 5 parts of isofraxidin.
A kind of preparation method of the Western medicine for treating chronic respiratory failure, concretely comprises the following steps：
First, in pharmaceutical grade clean area, BULBUS FRITILLARIAE CIRRHOSAE element glycosides, halofuginone hydrobromide, osmund ketone, 3- acetyl are weighed by above-mentioned metering ratio
Base -11- ketone group masticinic acids, silver forging glycosides, jateorrhizine hydrochloride, corynoline, support pool, lupeol, isofraxidin, sieve, machine
Tool adds ultra-pure water after mixing, in placing pharmacy mixer, mix 4min, controls RSD≤5%, and compressing tablet simultaneously do by low temperature after mixing
Dry, at 4 DEG C, packaging obtains final product the Western medicine for the treatment of chronic respiratory failure to temperature control.
Embodiment 3
A kind of Western medicine for treating chronic respiratory failure, be according to the primary raw material of weight portion：BULBUS FRITILLARIAE CIRRHOSAE 11 parts of glycosides of element, Changshan
27 parts of ketone, 9 parts of osmund ketone, 3 parts of 3- acetyl group -11- ketone groups masticinic acid, silver 18 parts of glycosides of forging, 14 parts of jateorrhizine hydrochloride, corynoline
9 parts, rely on pool 5 parts, 11 parts of lupeol, 6 parts of isofraxidin.
A kind of preparation method of the Western medicine for treating chronic respiratory failure, concretely comprises the following steps：
First, in pharmaceutical grade clean area, BULBUS FRITILLARIAE CIRRHOSAE element glycosides, halofuginone hydrobromide, osmund ketone, 3- acetyl are weighed by above-mentioned metering ratio
Base -11- ketone group masticinic acids, silver forging glycosides, jateorrhizine hydrochloride, corynoline, support pool, lupeol, isofraxidin, sieve, machine
Tool adds ultra-pure water after mixing, in placing pharmacy mixer, mix 6min, controls RSD≤5%, and compressing tablet simultaneously do by low temperature after mixing
Dry, at 6 DEG C, packaging obtains final product the Western medicine for the treatment of chronic respiratory failure to temperature control.
Embodiment 4
A kind of Western medicine for treating chronic respiratory failure, be according to the primary raw material of weight portion：BULBUS FRITILLARIAE CIRRHOSAE 11 parts of glycosides of element, Changshan
28 parts of ketone, 9 parts of osmund ketone, 3 parts of 3- acetyl group -11- ketone groups masticinic acid, silver 19 parts of glycosides of forging, 15 parts of jateorrhizine hydrochloride, corynoline
12 parts, rely on pool 7 parts, 11 parts of lupeol, 7 parts of isofraxidin.
A kind of preparation method of the Western medicine for treating chronic respiratory failure, concretely comprises the following steps：
First, in pharmaceutical grade clean area, BULBUS FRITILLARIAE CIRRHOSAE element glycosides, halofuginone hydrobromide, osmund ketone, 3- acetyl are weighed by above-mentioned metering ratio
Base -11- ketone group masticinic acids, silver forging glycosides, jateorrhizine hydrochloride, corynoline, support pool, lupeol, isofraxidin, sieve, machine
Tool adds ultra-pure water after mixing, in placing pharmacy mixer, mix 8min, controls RSD≤5%, and compressing tablet simultaneously do by low temperature after mixing
Dry, at 8 DEG C, packaging obtains final product the Western medicine for the treatment of chronic respiratory failure to temperature control.
Embodiment 5
A kind of Western medicine for treating chronic respiratory failure, be according to the primary raw material of weight portion：BULBUS FRITILLARIAE CIRRHOSAE 13 parts of glycosides of element, Changshan
30 parts of ketone, 10 parts of osmund ketone, 3 parts of 3- acetyl group -11- ketone groups masticinic acid, silver 20 parts of glycosides of forging, 16 parts of jateorrhizine hydrochloride, corydalis
14 parts of spirit, 8 parts of support pool, 12 parts of lupeol, 7 parts of isofraxidin.
A kind of preparation method of the Western medicine for treating chronic respiratory failure, concretely comprises the following steps：
First, in pharmaceutical grade clean area, BULBUS FRITILLARIAE CIRRHOSAE element glycosides, halofuginone hydrobromide, osmund ketone, 3- acetyl are weighed by above-mentioned metering ratio
Base -11- ketone group masticinic acids, silver forging glycosides, jateorrhizine hydrochloride, corynoline, support pool, lupeol, isofraxidin, sieve, machine
Tool adds ultra-pure water after mixing, in placing pharmacy mixer, mix 8min, controls RSD≤5%, and compressing tablet simultaneously do by low temperature after mixing
Dry, at 8 DEG C, packaging obtains final product the Western medicine for the treatment of chronic respiratory failure to temperature control.
Pharmacology test
1st, chronic toxicity test
With Western medicine obtained in the embodiment of the present invention 3 as test, using gastric infusion mode, successive administration 2 times in 24h,
Per minor tick 8h, 300mg/kg doses are administered every time, daily accumulation medicine total amount reaches 600mg medicines/kg, it is clinical equivalent to people to use
100 times of amount.After administration in 7d, mouse activity, feed, excretion are normal, well-grown, and hair color light, its average weight is equal
Increase with the prolongation of experimental period.Every mouse of post mortem at 8d, visually observe the heart, liver, spleen, lung, kidney, brain, thymus gland,
Stomach, intestines etc. do not find color and paramophia, fail to measure median lethal dose (LD50).As a result show：Western medicine of the present invention without
Chronic toxicity.
2nd, long term toxicity test
With Western medicine obtained in the embodiment of the present invention 3 as test, using gastric infusion mode, Western medicine of the present invention is divided into low dose
Amount, middle dosage, three groups of high dose, the drug dose of each group is respectively 60,120,180mg medicines/kg/d, equivalent to clinical dosage
10,20,30 times.After gastric infusion 24 weeks, medicine of the present invention refers to the general status of animal, hematological indices, blood biochemical
Mark without significantly impact, Systematic anatomy, organ coefficient and histopathological examination also no abnormal pathological change.Drug withdrawal 2
Also substantially change is had no week.As a result show：Western medicine of the present invention does not find that overt toxicity reacts and postpones in long term toxicity test
Toxic reaction.It can be seen that, Western medicine non-toxic reaction of the present invention, long-term prescription is safe and reliable.
3rd, clinical testing
In September, 2015 is male 125 to outpatient service and in hospital chronic respiratory failure 231 is collected between in March, 2016 altogether,
Female 106,25～70 years old age, average age 45.8 years old, the course of disease 1～15 year.
Diagnostic criteria：
According to the diagnostic criteria of national chronic respiratory failure clinical speciality meeting：(1) there are the cause of disease of respiratory failure, such as air flue
Occlusive disease, pulmonary parenchyma infiltration, pulmonary edema, Pulmonary Vascular disease, thorax and pleural diseases, anesthesia drug overdose, neuromuscular disease
Or sleep apnea syndrome etc.；(2) there are anoxic or the clinical manifestation with carbon dioxide retention, such as expiratory dyspnea, purple
Dark purple, Spirit nerve symptoms of disease etc..Occur the disturbance of consciousness, bulbar conjunctiva congestion and edema during concurrent pulmonary encephalopathy, papilledema, flutter
The wing trembles.Severe patient can have hemorrhage of digestive tract；(3) blood gas analysis：In sea-level atmosphere pressure, under quiescent condition, breathing is indoor
Air arterial partial pressure of oxygen (PaO2) ＜ 8.0kPa (60mmHg), carbon dioxide partial pressure (PaCO：＞ 6.6kPa) (50mmHg) (or
≤ normal).
Treatment method：
, according to Western medicine obtained in specific embodiment 3,2 times a day for the oral present invention, and total amount is taken daily for 6mg/kg, 5 days
For 1 course for the treatment of, 2 courses for the treatment of are taken.
Criterion of therapeutical effect：
It is effective：The clinical symptoms such as expiratory dyspnea, dry cough, crepitus (Velcro rales), cyanosis and sign are aobvious after treatment 15d
Write and take a turn for the better, blood gas index is clearly better；Effectively：Expiratory dyspnea, dry cough, crepitus (Velcro rales), cyanosis etc. after treatment 15d
Clinical symptoms and sign mitigate, and blood gas index takes a turn for the better；It is invalid：Clinical symptoms and sign, blood gas index do not change after treatment 15d
Kind or deterioration.
Treatment results：
In 231 patients, effective 182, effective 29, invalid 20, total effective rate 91.3%.
It is obvious to a person skilled in the art that the invention is not restricted to the details of above-mentioned one exemplary embodiment, Er Qie
In the case of spirit or essential attributes without departing substantially from the present invention, the present invention can be in other specific forms realized.Therefore, no matter
From the point of view of which point, embodiment all should be regarded as exemplary, and be nonrestrictive, the scope of the present invention is by appended power
Profit is required rather than described above is limited, it is intended that all in the implication and scope of the equivalency of claim by falling
Change is included in the present invention.
Moreover, it will be appreciated that although this specification is been described by according to embodiment, not each embodiment is only wrapped
Containing an independent technical scheme, this narrating mode of specification is only that for clarity those skilled in the art should
Using specification as an entirety, the technical scheme in each embodiment can also Jing it is appropriately combined, form those skilled in the art
Understandable other embodiment.
Claims (5)
1. a kind of Western medicine for treating chronic respiratory failure, it is characterised in that the primary raw material according to weight portion is：BULBUS FRITILLARIAE CIRRHOSAE element glycosides
9-13 parts, halofuginone hydrobromide 25-30 parts, osmund ketone 7-10 parts, 3- acetyl group -11- ketone group masticinic acid 2-3 parts, silver forging glycosides 15-20 parts,
Jateorrhizine hydrochloride 8-16 parts, corynoline 5-14 parts, support pool 2-8 parts, lupeol 9-12 parts, isofraxidin 5-7 parts.
2. it is according to claim 1 treatment chronic respiratory failure Western medicine, it is characterised in that the treatment chronic respiratory declines
The Western medicine for exhausting, be according to the primary raw material of weight portion：BULBUS FRITILLARIAE CIRRHOSAE element glycosides 10-11 parts, halofuginone hydrobromide 26-28 parts, osmund ketone 8-9 parts,
3- acetyl group -11- ketone group masticinic acid 2-3 parts, silver forging glycosides 16-19 parts, jateorrhizine hydrochloride 12-15 parts, corynoline 7-12 parts, according to
Support pool 3-7 parts, lupeol 10-11 parts, isofraxidin 5-7 parts.
3. it is according to claim 1 and 2 treatment chronic respiratory failure Western medicine, it is characterised in that the treatment is chronic to exhale
The Western medicine of exhaustion is inhaled, is according to the primary raw material of weight portion：BULBUS FRITILLARIAE CIRRHOSAE 11 parts of glycosides of element, 27 parts of halofuginone hydrobromide, 9 parts of osmund ketone, 3- second
3 parts of acyl group -11- ketone groups masticinic acid, silver 18 parts of glycosides of forging, 14 parts of jateorrhizine hydrochloride, 9 parts of corynoline, support pool 5 parts, lupin
11 parts of alcohol, 6 parts of isofraxidin.
4. it is a kind of as described in claim 1-3 is arbitrary treatment chronic respiratory failure Western medicine preparation method, it is characterised in that
Concretely comprise the following steps：
First, in pharmaceutical grade clean area, by above-mentioned metering ratio weigh BULBUS FRITILLARIAE CIRRHOSAE element glycosides, halofuginone hydrobromide, osmund ketone, 3- acetyl group-
11- ketone group masticinic acids, silver forging glycosides, jateorrhizine hydrochloride, corynoline, support pool, lupeol, isofraxidin, sieve, and machinery is mixed
Addition ultra-pure water after even, in placing pharmacy mixer, mixes 4-8min, controls RSD≤5%, compressing tablet and low temperature drying after mixing,
At 4-8 DEG C, packaging obtains final product the Western medicine for the treatment of chronic respiratory failure to temperature control.
5. it is according to claim 4 treatment chronic respiratory failure Western medicine preparation method, it is characterised in that concrete steps
Middle mixing 6min.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611189083.9A CN106619680A (en) | 2016-12-21 | 2016-12-21 | Western medicine for treating chronic respiratory failure |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611189083.9A CN106619680A (en) | 2016-12-21 | 2016-12-21 | Western medicine for treating chronic respiratory failure |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106619680A true CN106619680A (en) | 2017-05-10 |
Family
ID=58833756
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611189083.9A Withdrawn CN106619680A (en) | 2016-12-21 | 2016-12-21 | Western medicine for treating chronic respiratory failure |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106619680A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104906439A (en) * | 2015-07-03 | 2015-09-16 | 李慧 | Medicine for treating chronic respiratory failure |
-
2016
- 2016-12-21 CN CN201611189083.9A patent/CN106619680A/en not_active Withdrawn
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104906439A (en) * | 2015-07-03 | 2015-09-16 | 李慧 | Medicine for treating chronic respiratory failure |
Non-Patent Citations (3)
| Title |
|---|
| 尚严 等: "HPLC法测定胡颓子叶中银锻苷的含量", 《中国药师》 * |
| 张东 等: "中药紫萁贯众中紫萁酮的分离及含量测定", 《中国药学杂志》 * |
| 王鹏 等: "常山酮防治放射性肺损伤及其机制的研究", 《中国肿瘤临床》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8394423B2 (en) | Compositions comprising apocynin, ginkgo and ginger and uses thereof | |
| CN102633831A (en) | Methyl phosphorus propofol disodium dihydrate and preparation method and application thereof | |
| Hirst et al. | Lung deposition of budesonide from the novel dry powder inhaler AirmaxTM | |
| CN104825778B (en) | A kind of Chinese medicine composition for being used to treat calf pneumonia | |
| CN106619680A (en) | Western medicine for treating chronic respiratory failure | |
| CN106692480A (en) | Western medicine for treating ventilation function failure | |
| CN106728286A (en) | It is a kind of to treat Chinese and western medicinal composition of chronic respiratory failure and preparation method thereof | |
| CN106727600A (en) | It is a kind of to treat Chinese and western medicinal composition of bronchial astehma and preparation method thereof | |
| Marshik et al. | A novel breath actuated device (Autohaler™) consistently actuates during the early phase of inspiration | |
| CN102872324B (en) | Traditional Chinese medicine atomized mixture for treating chest surgery postoperative respiratory distress syndrom | |
| CN105362226B (en) | The preparation method of ambroxol albuterol aerosol | |
| CN104189076B (en) | A kind of Traditional Chinese medicine plaster for treating children's cold asthma and preparation method thereof | |
| CN108553554A (en) | A kind of suppository and preparation method thereof for treating fever in children, palpitation with fear uneasiness, lung heat many coughs of phlegm | |
| CN106727494A (en) | A kind of Western medicine for treating Eaton agent pneumonia | |
| CN108245615A (en) | A kind of composition for treating respiratory disease, suction-type Chinese medicine preparation and preparation method | |
| CN106511665A (en) | Pharmaceutical for treating allergic pneumonia | |
| CN106215080A (en) | A kind of pharmaceutical composition for the treatment of bronchial asthma of child containing Procaterol Hydrochloride and preparation method thereof | |
| CN115990223B (en) | Application of composition in preparing medicine for assisting in treating chronic obstructive pulmonary disease | |
| CN106619686A (en) | Western medicine for treating bronchiectasis | |
| Dikensoy et al. | Severe asthma attack in a patient with premenstrual asthma: hot pepper is the possible trigger | |
| CN106668599A (en) | Drug for treating bronchiectasis | |
| CN106729318A (en) | A kind of medicine for treating acute respiratory failure | |
| CN105496993A (en) | Preparing method of ambroxol salbutamol controlled release granule | |
| Said et al. | 1003 Randomized Controlled Trial on Early L-Carnitine Supplementation to Preterm Newborns with Respiratory Distress Syndrome. Does it Influence Neonatal Wellbeing? | |
| CN106619629A (en) | Western medicine for treating acute respiratory failure |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20170510 |